MA33199B1 - Compositions de vaccin et procédés pour le traitement de la mucormycose et d'autres maladies fongiques - Google Patents
Compositions de vaccin et procédés pour le traitement de la mucormycose et d'autres maladies fongiquesInfo
- Publication number
- MA33199B1 MA33199B1 MA34256A MA34256A MA33199B1 MA 33199 B1 MA33199 B1 MA 33199B1 MA 34256 A MA34256 A MA 34256A MA 34256 A MA34256 A MA 34256A MA 33199 B1 MA33199 B1 MA 33199B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- vaccine compositions
- mucormycosis
- fungal diseases
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
La présente invention concerne des compositions thérapeutiques et des procédés pour traiter ou prévenir une maladie ou des affections fongiques comprenant la mucormycose. Les procédés thérapeutiques et les compositions de l'invention comprennent des compositions de vaccin ayant un polypeptide FTR ou un fragment antigénique du polypeptide; un vecteur comprenant une séquence nucléotidique qui est sensiblement complémentaire d'au moins 18 nucléotides contigus de séquence FTR; un antisens; un petit ARN interférant ou un anticorps inhibiteur de FTR. Les compositions de vaccin de l'invention peuvent comprendre en outre un adjuvant.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16161409P | 2009-03-19 | 2009-03-19 | |
PCT/US2010/000820 WO2010107500A1 (fr) | 2009-03-19 | 2010-03-19 | Compositions de vaccin et procédés pour le traitement de la mucormycose et d'autres maladies fongiques |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33199B1 true MA33199B1 (fr) | 2012-04-02 |
Family
ID=42739922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34256A MA33199B1 (fr) | 2009-03-19 | 2010-03-19 | Compositions de vaccin et procédés pour le traitement de la mucormycose et d'autres maladies fongiques |
Country Status (16)
Country | Link |
---|---|
US (2) | US20120093828A1 (fr) |
EP (1) | EP2408804A4 (fr) |
JP (1) | JP2012520878A (fr) |
KR (1) | KR20110139743A (fr) |
CN (1) | CN102639557A (fr) |
AU (1) | AU2010226320A1 (fr) |
CA (1) | CA2755273A1 (fr) |
CL (1) | CL2011002284A1 (fr) |
IL (1) | IL215093A0 (fr) |
MA (1) | MA33199B1 (fr) |
MX (1) | MX2011009735A (fr) |
NZ (2) | NZ614255A (fr) |
RU (1) | RU2011142173A (fr) |
SG (1) | SG174413A1 (fr) |
TN (1) | TN2011000459A1 (fr) |
WO (1) | WO2010107500A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1403092B1 (it) * | 2010-12-01 | 2013-10-04 | Univ Degli Studi Modena E Reggio Emilia | Metodo per la diagnosi e/o il monitoraggio della mucormicosi. |
EP2755681B1 (fr) | 2011-09-15 | 2018-06-27 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | IMMUNOTHÉRAPIE ET DIAGNOSTIC DE LA MUCORMYCOSE AU MOYEN DE CotH |
US20160017293A1 (en) * | 2012-08-15 | 2016-01-21 | Neostem Oncology, Llc | Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same |
CN106590685A (zh) * | 2015-10-19 | 2017-04-26 | 粮华生物科技(北京)有限公司 | 重金属污染土壤的原位生物修复制剂和修复方法 |
WO2020006438A1 (fr) * | 2018-06-29 | 2020-01-02 | University Of Maryland, Baltimore | Méthodes de traitement ou de prévention de la mucormycose |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6100380A (en) * | 1991-10-28 | 2000-08-08 | Cytran, Inc. | Immunomodulating peptides and methods of use |
PH31594A (en) | 1993-09-30 | 1998-11-03 | Janssen Pharmaceutica Nv | Oral formulations on an antifungal. |
TW533205B (en) * | 1996-06-25 | 2003-05-21 | Novartis Ag | Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition |
DE50111949D1 (de) * | 2000-12-16 | 2007-03-15 | Alstom Technology Ltd | Komponente einer Strömungsmaschine |
BR0206312A (pt) * | 2001-01-04 | 2004-02-17 | Univ Saskatchewan | Composição de vacina, uso sobrenadante de cultura celular de escherichia coli enteroemorrágica (ehec), e, métodos para a geração de uma resposta imunológica em um mamìfero contra um antìgeno de escherichia coli enteroemorrágica (ehec) secretado, e 0157:h7 enteroemorrágica (ehec 0157:h7) secretado, e para a redução da colonização de escherichia coli enteroemorrágica (ehec) em um ruminante |
US7363166B2 (en) * | 2001-03-30 | 2008-04-22 | Council Of Scientific & Industrial Research | Computational method for the identification of candidate proteins useful as anti-infectives |
WO2003018051A1 (fr) * | 2001-08-27 | 2003-03-06 | Vic Jira | Composition antifongique |
GB0223978D0 (en) | 2002-10-15 | 2002-11-20 | Novartis Ag | Organic compound |
ITMI20022447A1 (it) | 2002-11-19 | 2004-05-20 | Carlo Ghisalberti | Uso di piridinoni nel trattamento della purpura capillare ed affezioni cutanee correlate. |
MXPA05007156A (es) | 2002-12-31 | 2005-09-21 | Nektar Therapeutics | Formulacion farmaceuticas aerosolizable para terapia para infecciones fungicas. |
US7226600B2 (en) * | 2003-06-11 | 2007-06-05 | Ultra Biotech Limited | Method to prepare compositions comprising yeast treated with electromagnetic energy |
CA2550927A1 (fr) * | 2003-12-23 | 2005-07-14 | Glaxosmithkline Biologicals S.A. | Bacterie gram-negative comportant un niveau de lps reduit dans la membrane externe et utilisation de celle-ci pour traiter une infection bacterienne gram-negative |
US7588931B2 (en) * | 2004-11-04 | 2009-09-15 | E. I. Du Pont De Nemours And Company | High arachidonic acid producing strains of Yarrowia lipolytica |
EP2221382A3 (fr) * | 2006-03-24 | 2010-12-01 | BASF Plant Science GmbH | Protéines associées à une réponse au stress abiotique et homologues |
CL2007002026A1 (es) * | 2006-07-13 | 2008-06-06 | Los Angeles Biomed Res Inst | Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica. |
-
2010
- 2010-03-19 CN CN2010800212819A patent/CN102639557A/zh active Pending
- 2010-03-19 KR KR1020117024522A patent/KR20110139743A/ko not_active Application Discontinuation
- 2010-03-19 AU AU2010226320A patent/AU2010226320A1/en not_active Abandoned
- 2010-03-19 MX MX2011009735A patent/MX2011009735A/es active IP Right Grant
- 2010-03-19 MA MA34256A patent/MA33199B1/fr unknown
- 2010-03-19 US US13/257,585 patent/US20120093828A1/en not_active Abandoned
- 2010-03-19 CA CA2755273A patent/CA2755273A1/fr not_active Abandoned
- 2010-03-19 WO PCT/US2010/000820 patent/WO2010107500A1/fr active Application Filing
- 2010-03-19 JP JP2012500790A patent/JP2012520878A/ja active Pending
- 2010-03-19 SG SG2011066602A patent/SG174413A1/en unknown
- 2010-03-19 NZ NZ61425510A patent/NZ614255A/en not_active IP Right Cessation
- 2010-03-19 EP EP10753820A patent/EP2408804A4/fr not_active Withdrawn
- 2010-03-19 US US12/661,609 patent/US8444985B2/en not_active Expired - Fee Related
- 2010-03-19 NZ NZ595271A patent/NZ595271A/xx not_active IP Right Cessation
- 2010-03-19 RU RU2011142173/10A patent/RU2011142173A/ru not_active Application Discontinuation
-
2011
- 2011-09-09 TN TN2011000459A patent/TN2011000459A1/fr unknown
- 2011-09-11 IL IL215093A patent/IL215093A0/en unknown
- 2011-09-15 CL CL2011002284A patent/CL2011002284A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP2408804A4 (fr) | 2012-10-03 |
CA2755273A1 (fr) | 2010-09-23 |
MX2011009735A (es) | 2011-10-19 |
EP2408804A1 (fr) | 2012-01-25 |
NZ614255A (en) | 2015-03-27 |
US8444985B2 (en) | 2013-05-21 |
KR20110139743A (ko) | 2011-12-29 |
WO2010107500A1 (fr) | 2010-09-23 |
US20120093828A1 (en) | 2012-04-19 |
SG174413A1 (en) | 2011-10-28 |
TN2011000459A1 (en) | 2013-03-27 |
AU2010226320A1 (en) | 2011-10-13 |
CN102639557A (zh) | 2012-08-15 |
JP2012520878A (ja) | 2012-09-10 |
NZ595271A (en) | 2013-08-30 |
IL215093A0 (en) | 2011-11-30 |
RU2011142173A (ru) | 2013-04-27 |
US20100285024A1 (en) | 2010-11-11 |
CL2011002284A1 (es) | 2012-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023072074A (ja) | Burkholderia感染の処置のための組成物および方法 | |
TWI377212B (en) | Human monoclonal antibodies to influenza m2 protein and methods of making and using same | |
JP6643981B2 (ja) | インフルエンザウイルスワクチンおよびその使用 | |
JP2010516290A5 (fr) | ||
US20140004156A1 (en) | Biological inhibitors of ror1 capable of inducing cell death | |
MA33199B1 (fr) | Compositions de vaccin et procédés pour le traitement de la mucormycose et d'autres maladies fongiques | |
MX2009006760A (es) | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas. | |
MXPA05011110A (es) | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos. | |
JP2010150280A5 (fr) | ||
JP2011522842A (ja) | パーキンソン病に関連する症状の治療のための化合物 | |
JP2018528763A (ja) | バイオフィルムの除去のためのペプチドおよび抗体 | |
WO2010044889A3 (fr) | Isolats de torque teno virus (ttv) et compositions associées | |
RU2012107993A (ru) | Полипептиды porhyromonas gingivalis | |
RU2015102027A (ru) | Проникающие в клетку пептиды и способы идентификации проникающих в клетку пептидов | |
JP2015522264A5 (fr) | ||
JP2022166193A (ja) | インターフェロンレベルを低下させるのに有用な化合物 | |
JP2014528715A5 (fr) | ||
Onara et al. | Differential transcription of multiple forms of alpha-2-macroglobulin in carp (Cyprinus carpio) infected with parasites | |
JP5746038B2 (ja) | Cnsの炎症性疾患の治療のための化合物および方法 | |
CZ303409B6 (cs) | Zkrácený a mutovaný lidský chemokin | |
EP1765851A4 (fr) | Composes analogues de peptides analgesiques derives du venin de serpents crotalus durissus terrificus, leurs applications, compositions et procedes destines a la preparation et a la purification de ces composes | |
AU2016263534A1 (en) | Treatment and detection of trypanosomes | |
MX2012004448A (es) | Clones infecciosos de torque teno virus. | |
JP2023526218A (ja) | 生体高分子標的特異的補体阻害剤及びその製造方法と応用 | |
MA33668B1 (fr) | Anticorps chimériques spécifiques pour cd151 et leur utilisation dans le traitement du cancer |